111
Participants
Start Date
October 26, 2022
Primary Completion Date
June 30, 2025
Study Completion Date
July 31, 2027
P1101 (Ropeginterferon alfa-2b-njft)
Ropeginterferon alfa-2b-njft
Ropeginterferon alfa-2b-njft (P1101)
Ropeginterferon alfa-2b-njft
Mount Sinai, New York
Montefiore Medical Center, The Bronx
American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders), Bethesda
University of Virginia - Emily Couric Cancer Center, Charlottesville
Wake Forest Baptist Medical Center, High Point
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
East Carolina University, Greenville
Baptist MD Anderson, Jacksonville
University of Tennessee Health Science Center, Memphis
Mercy Health, Paducah
Fort Wayne Medical Oncology and Hematology, Fort Wayne
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Westwood
Tulane University Medical Center, New Orleans
MD Anderson, Houston
University of Utah, Salt Lake City
Astera HealthCare, East Brunswick
Tom Baker Cancer Centre, Calgary
St. Paul's Hospital, Vancouver
Juravinski Cancer Center - Hamilton Health Sciences, Hamilton
Princess Margaret Hospital, Toronto
The Ottawa Hospital, Ottawa
St. Michael's Hospital, Toronto
Lead Sponsor
PharmaEssentia
INDUSTRY